| Non-Small Cell Lung Carcinoma
Cyramza vs Mektovi
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Cyramza vs Mektovi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMektovi has a higher rate of injection site reactions vs Cyramza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Mektovi but not Cyramza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cyramza
Mektovi
At A Glance
IV infusion
Every 2 weeks
VEGFR2 antagonist
Oral
Twice daily
MEK inhibitor
Indications
- Gastric Adenocarcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Liver carcinoma
- melanoma
- Non-Small Cell Lung Carcinoma
Dosing
Gastric Adenocarcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent or in combination with weekly paclitaxel.
Non-Small Cell Lung Carcinoma (EGFR exon 19/21, first-line) 10 mg/kg every 2 weeks by IV infusion in combination with erlotinib.
Non-Small Cell Lung Carcinoma (post-platinum progression) 10 mg/kg by IV infusion on Day 1 of a 21-day cycle in combination with docetaxel.
Metastasis from malignant neoplasm of colon and/or rectum 8 mg/kg every 2 weeks by IV infusion prior to FOLFIRI.
Liver carcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent.
melanoma 45 mg orally twice daily in combination with encorafenib; reduce to 30 mg orally twice daily for patients with moderate or severe hepatic impairment.
Non-Small Cell Lung Carcinoma 45 mg orally twice daily in combination with encorafenib.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Hypertension, fatigue/asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, stomatitis, proteinuria, thrombocytopenia, decreased appetite, nausea.
Serious Febrile neutropenia, pneumonia, hemorrhage, gastrointestinal perforation, arterial thromboembolic events, impaired wound healing, posterior reversible encephalopathy syndrome, proteinuria including nephrotic syndrome, infusion-related reactions, sepsis.
Postmarketing Thrombotic microangiopathy, hemangioma, dysphonia, arterial aneurysms/dissections/rupture, heart failure.
Most common (>=25%) fatigue, nausea, diarrhea, vomiting, abdominal pain, musculoskeletal pain, visual impairment, constipation, dyspnea, rash, cough
Serious hemorrhage, diarrhea, anemia, dyspnea, pneumonia, arrhythmia, device related infection, edema, myocardial infarction, pleural effusion
Pharmacology
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D, inhibiting ligand-stimulated activation of VEGFR2 and thereby inhibiting endothelial cell proliferation, migration, and angiogenesis.
Binimetinib is a reversible inhibitor of MEK1 and MEK2, upstream regulators of the ERK pathway; combined with encorafenib it targets two different kinases in the RAS/RAF/MEK/ERK pathway for greater anti-proliferative and anti-tumor activity in BRAF mutation-positive tumors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cyramza
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Mektovi
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Cyramza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Mektovi
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Cyramza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Mektovi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cyramza.
$0/fillfill
Mektovi Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyramzaView full Cyramza profile
MektoviView full Mektovi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.